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ABSTRACT 
Introducing PCR products into plasmids vectors is key for molecular techniques. Ideally cloning vectors are easy to 
construct, modify and propagate, neither require advanced techniques nor special equipment or reagents and efficiently 
incorporate PCR products at close to zero empty vector background. We provide an easy to engineer self-made cloning 
vector, neither requiring sophisticated tools or techniques nor advanced cloning knowledge. Through recombination we 
obtained the pUC18ccdB vector, carrying the ccdB suicide gene within the pUC18 backbone. When SmaI cleaved 
(within the ccdB) vector was T4 ligated with small (0.2 kbp) and intermediate (1.3 to 2.2 kbp) blunt end PCR-products 
and transformed into E. coli, the amount of clones with incorporated PCR product was comparable to commercial 
PCR-cloning kits and at a close to zero PCR product negative background. In conclusion we present a simple, versatile 
and cheap approach to an efficient “home made” PCR-cloning vector that allows integration of crude blunt end PCR 
products at close to zero background. 
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1. Introduction 
Cloning of polymerase chain reaction (PCR) products 
into plasmids of Escherichia coli (E. coli) is crucial for 
molecular techniques [1]. Numerous systems have been 
proposed and many have been commercialized allowing 
to introduce PCR products into plasmids. Most PCR- 
cloning vectors share three key features: 1) incorporation 
of the PCR product into a circular plasmid DNA; 2) 
selection of E. coli clones that have incorporated the 
plasmid; and 3) selection of clones that contain the PCR- 
product of interest [2]. 
For studies in which highest possible cloning effi- 
ciency is not essential, minimal workload would be de- 
sired such as direct cloning of blunt ended products from 
PCR reactions obtained by proof reading polymerase rea- 
ctions. Ligation of such blunt ended DNA products lack- 
ing sticky ends or TA-overhangs however result in re- 
duced ligation efficiency into the PCR cloning vector [3]. 
Thus efficient elimination of E. coli without plasmid up- 
take and removal of empty vector background through 
efficient selection of clones with incorporated PCR-pro- 
ducts is required. 
Selection for plasmid uptake is usually performed by 
encoding an antibiotic resistance gene within the PCR 
cloning plasmid [2]. When grown in the presence of an- 
tibiotics only bacteria carrying the plasmid encoding a 
matching resistance gene can survive. To further select 
for PCR-product incorporation numerous approaches 
with various efficiency and limitations have been used. 
Some need labor intensive procedures such as dephos- 
phorylation of the linearized vector preventing religation 
unless a phosphorlylated DNA-fragment is interposed [4]. 
The use of a blunt end restriction site which is destroyed 
as a result of incorporating a PCR fragment has also suc- 
cessfully been used [5]. Alternatively the vector can be 
engineered such that incorporation of the PCR-product 
affects a selection marker. Either the gene itself or its 
promoter is disrupted and becomes dysfunctional after 
the insertion event [6]. A commonly used example of this 
selection technique is “blue/white selection” based on 
disruption of the β-galactosidase reporter gene [6,7]. Al- 
though this method became commercialized and is com- 
monly used, this ‘negative-selection’ technique cannot be 
used in the presence of high background due to religa- 
tion of non-recombinant clones. Alternatively toxic repor- 
ter genes were developed that allow direct elimination of 
*These authors contributed equally to this article. 
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non-recombinant clones resulting in efficient selection 
for vectors with incorporated DNA [8-11]. Such “posi- 
tive-selections” can virtually eliminate empty vector pla- 
smids carrying clones. One example of toxic genes used 
for positive-selection is the ccdB gene product which 
traps gyrase and kills most E. coli strains [8] usually used 
for molecular techniques. As an exception strains carry- 
ing a mutation within DNA gyrase (gyrA462) are resis- 
tant to the ccdB gene product [12,13] and thus allow pro- 
pagation of ccdB carrying vectors. 
Herein we describe a simple and cheap way to engi- 
neer and propagate a PCR-cloning vector which allows 
everybody to efficiently clone blunt ended PCR products 
with a close to zero background. 
2. Methods 
2.1. Bacterial Strains and Plasmids 
We used the E. coli strains XL1Blue (Stratagene, CA) 
and ccdB resistant One Shot® ccdB Survival™ (Invitro- 
gen, NY) cells. Cells were grown in Luria-Bertani me- 
dium (LB) and rendered chemically competent by incu- 
bation on ice with TfB1 (RbCl 100 mM, MnCl2. 50 mM, 
KOAc, 30 mM, CaCl2. 10 mM and glycerol 15% v/v) 
and TfB2 (RbCl 100 mM, CaCl2. 10 mM, glycerol 15% 
v/v) then frozen in liquid nitrogen until further used for 
transformation. 
2.2. Reagents 
DNA modifying enzymes were purchased from New 
England BioLabs (NEB; MA, USA); restriction enzymes 
used were BamH1, EcoR1, Pst1 and SmaI, polymerases 
used were Taq and Pfu Phusion and for DNA ligation T4 
DNA ligase. All enzymes were used according to the 
recommendations of the manufactor in conjunction with 
recommended buffers. As a reference for PCR cloning 
efficiency commercial TA-cloning vector pCR® 2.1- 
TOPO (Invitrogen) was used in conjunction with PCR 
products carrying 5’-A overhangs (resulting from incu- 
bation with Taq DNA polymerase). PCR cleanup and 
plasmid extraction kits were purchased from Macherey 
Nagel (Düren, Germany). LB and super Optimal Broth 
containing 20 mM of glucose (SOC medium) were made 
and sterilized following standard protocols. 
2.3. Construction of the pUC18ccdB Cloning  
Plasmid 
pDONRTM207 (Invitrogen) was digested with Pst1 re- 
striction sites and the agarose gel purified 1829 base pair 
(bp) ccdB gene containing fragment was introduced into 
the single Pst1 cut pUC18 (Aligent, NL) using T4 DNA 
ligase (NEB) (Figure S1). To analyze the orientation of 
the ccdB fragment incorporation diagnostic digests were 
performed. In clones in which the ccdB and ampicillin 
resistance (AmpR) genes were oriented in the same direc- 
tion digestion with EcoRI and BamHI yielded a 725 bp 
fragment. The opposite orientation of the two genes yiel- 
ded a 1161 bp fragment (Figure S2). To eliminate one of 
the two SmaI restriction sites and to decrease plasmid 
size a 746 bp fragment was removed by EcoRI digestion 
of a clone in which ccdB and AmpR were aligned. The 
linear EcoRI cut 3769 bp long backbone was self-ligated 
(T4 ligase). The resulting circular modified pUC18 plas- 
mid containing the ccdB gene (pUC18ccdB) shown in 
Figure 1 was verified by sequencing, and functionality 
of the ampicillin and ccdB genes were verified (Figure 
S3). pUC18ccdB was amplified in and isolated from One 
Shot® ccdB Survival™ cells, purified then linearized by a 
single cut event in the ccdB gen using the SmaI restric- 
tion enzyme. Linear pUC18ccdB was stored frozen until 
usage for PCR cloning. 
2.4. Synthesis of PCR Products for Cloning 
We generated a 237 bp long PCR product using an al- 
kaline phosphatase gene carrying plasmid [14,15], the 
primers provided in Table S1 and Pfu Phusion poly- 
merase (NEB). PCR was carried out according to the ma- 
nufactor’s instructions. To make the PCR product also 
suited for TA-cloning a proportion of the PCR reaction 
mix was incubated 20 minutes at 70˚C with Taq DNA 
polymerase and fresh dNTP (both from NEB). All PCR 
products were cleaned (NucleoSpin Extract П Kit; Ma- 
cherey-Nagel) before T4 ligation reaction. 
To generate larger PCR products, cDNA derived from 
mouse liver was amplified using Pfu Phusion (NEB) fol- 
lowing the manufactor’s instructions. Primer pairs used 
to generate the two 1.3 kbp products (CDS encoding 
 
 
Figure 1. Scheme of pUC18, pDONRTM207 and pUC18ccdB 
vectors. Shown are the ampicilin resistance gene (AmpR) 
with promotor (AmpR prom.), the β-Galactosidase encod- 
ing gene (lacZ) with promotor (lac prom.), the canamycin 
resistance mediating gene (CAT/CamR) with promotor and 
the ccdB suicide gene (ccdB) targeting gyrase as well as re- 
striction sites. 
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protease activated receptor (PAR)-3 and PAR4) and the 
2.2 kbp product (CDS encoding thrombomodulin) are 
provided in Table S1. 
2.5. Analysis of DNA 
DNA was separated by 1% agarose gels, stained with 
ethidium bromide and analyzed using a CCD camera 
(BioRad, München, Germany). One kb ladder from Pro- 
mega was used as reference. Commercial DNA sequenc- 
ing was performed by Microsynth (Balgach, Switzer- 
land). 
2.6. PCR Product Incorporation into Linear  
Plasmid and Transformation of Competent  
Cells 
Equal amounts (0.075 pmol) of SmaI linearized  
pUC18ccdB blunt ended PCR products were incubated 
over night at 16˚C with T4 DNA ligase (NEB) according 
to the manufactor’s instruction. As control reaction PCR 
cloning using the pCR®-XL-TOPO® vector kit (Invitro- 
gen) was used. The Manufactor’s protocol was follow- 
ed (30 minutes incubation of 1 μL of pCR®-XL-TOPO® 
vector reagent with 4 μL of gel purified PCR product 
(~0.6 pmol) with deoxyadenosin 3’ ends).  
Either of the reaction products (5 μL) were incubated 
30 minutes on ice with 15 μL of competent XL1Blue 
cells, heat shocked, then propagated in SOC medium 
(37˚C shaking, 1 hour) and 20 - 100 μL of transformed 
cells were plated on LB-agar plates containing 100 mg/L 
of ampicillin. Clones were picked and analyzed after 14 - 
24 hours of incubation at 37˚C. 
2.7. Statistics 
Confidence intervals on proportion were calculated with 
aid of the NCSS software package based on F distribu- 
tion. 
3. Results 
The hybrid plasmid pUC18ccdB was obtained by recom- 
bination of the commercial pUC18 and pDONOR207 
plasmids followed by removal of the SmaI restriction site 
within the pUC18’s multi cloning site (Figure 1). Se- 
quencing excluded non desired mutations within the 
newly constructed pUC18ccdB plasmid. 
3.1. Assessing Cloning Efficiency of a Small PCR  
Product in pUC18ccdB 
To test if pUC18ccdB can be used for direct cloning of 
PCR fragments we generated a blunt ended short (237 bp) 
PCR product and tested overall efficiency of incurpora- 
tion within pUC18ccdB. We inserted the 273 bp PCR 
product into SmaI linearized pUC18ccdB. For compare- 
son of efficiency the same PCR product was extended 
with 3’A-overhangs (incubation with Taq polymerase) 
and inserted into commercial pCR®-XL-TOPO® vector. 
Reactions with either plasmid vector resulted in abundant 
transformants and all clones screened yielded the cor- 
rectly inserted PCR fragment (Table 1). 
3.2. Utility of pUC18ccdB in Cloning Medium  
Size PCR Products 
PCR cloning vectors are often used for direct cloning of 
or introduction of mutations into already obtained coding 
sequences (CDS). We thus tested whether pUC18ccdB 
can be used to clone PCR products of mouse CDS rang- 
ing between 1.3 and 2.2 kbp in size. Reaction conditions 
were used as described above and resulted in numerous 
transformants. These were screened for PCR product in- 
corporation. We found all clones analyzed to have cor- 
rectly incorporated both of the 1.3 kbp PCR products 
(CDS of PAR3 and 4).Similarly in 6 out of the 7 clones 
analyzed the 2.2 kbp CDS (encoding thrombomodulin) 
was present. The overall success rate for the pUC18ccdB 
vector to provide a correctly incorporated medium sized 
PCR product was 94% (95% confidence interval (CI95%) 
73% to 98%) with a 100% (CI95% 63% to 100%) success 
rate for 1.3 kb PCR products and a 86% success rate 
(CI95% 52% to 99%) for 2.2 kbp PCR products (Table 2). 
Our results demonstrate that short to mid-sized blunt 
end PCR fragments can efficiently be cloned into the 
pUC18ccdB vector at a close to zero empty vector back- 
ground [12,13]. 
4. Discussion 
Through simple recombination of two commonly used 
and commercially available vectors we obtained the no- 
vel pUCccdB PCR cloning vector. In contrast to most 
commercial cloning vectors, this plasmid can easily be 
propagated without special reagents or equipment. In 
contrast to similar constructs made so far, which were 
more cumbersome to obtain, this plasmid can be made by 
research groups with limited budget and knowledge al- 
 
Table 1. Yield of short PCR product containing transfor- 
mants. 
PCR  
fragment Vector
Colonies/
plate 
Clones positive/ 
analyzed 
CI0.95 [%] for PCR 
product 
incorporation 
237bp; 
blunt pUCccdB >20 6/6 60 - 100 
237bp with 
3’-A  
overhangs
pCR®2.1-
TOPO >20 3/3 40 - 100
* 
*Expected yield of 80% according to manufactor. 
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Table 2. Yield of intermediate sized PCR product contain- 
ing transformants. 
PCR fragment Vector 
Positive/ 
analyzed 
clones 
CI0.95 [%] for PCR 
product  
incorporation 
CDS (PAR3),  
1.3 kbp, blunt pUC18ccdB 7/7 63 - 100 
CDS (PAR4),  
1.3 kbp, blunt pUC18ccdB 7/7 63 - 100 
CDS  
(Thrombomodulin),  
2.2 kbp, blunt 
pUC18ccdB 6/7 52 - 99 
 
lowing them to easily rebuild this versatile PCR cloning 
vector. 
Many vectors from commercial PCR-cloning kits such 
as the TOPO® or PCR2.1® series are marketed as linea- 
rized vectors thus precluding amplification and modi- 
fication. In contrast to these, pUCccdB can easily be am- 
plified in commercially available E. coli [12,13] car- 
rying the gyrA462 mutation. This opens up possibilities 
for modification of the ccdB selection gene [16] or the 
vector backbone and thus further adds to versatility. Re- 
building of pUCccdB along the lines we propose only 
relies on very basic PCR and cloning skills and limited 
labor. 
We have compared cloning efficiency of pUC18ccdB 
with the commercially available highly efficient PCR 
cloning kit pCR®2.1-TOPO. Whereas pUC18ccdB relies 
on positive selection through disruption of the ccdB sui- 
cide gene, pCR®2.1-TOPO relies on vaccinia virus de- 
rived topoisomerase I. This enzyme binds to the vector, 
cleaves the phosphodiester backbone after 5’-CCCTT at 
either end of the linearized vector [17] to then bind both 
the backbone and the 3’-A of the PCR product before 
efficiently ligating the two ends. We found both methods 
to be highly efficient and to result in aboundant trans- 
formants with incorporated PCR products. Incorporation 
depending on topoisomerase I however requires an ad- 
ditional reaction step following amplification of the PCR 
product, i.e. the addition of 3’ A overhangs by incubation 
with Taq polymerase. 
An important characteristic of positive selection sys- 
tems is the tightness of suppression in transformants that 
failed PCR product incorporation while offering efficient 
deletion of the selection marker upon incorporation of 
the PCR product. Excellent suppressive proprieties of the 
ccdB gene product are underscored by the fact that this 
marker is widely used [8] and has been commercialized 
(e.g. gateway vector family; Invitrogen). Efficient selec- 
tion of transformants with incorporated PCR plasmids 
however also requires successful disruption of the sui- 
cide gene upon PCR product incorporation. Multiple me- 
chanisms blunt the gene product function and include 
premature introduction of a stop codon [4], introduction 
of a frame shift altering the gene product 3’ of the incor- 
poration site [4] or introduction of an additional protein 
stretch within the ccdB gene product. Whereas the first 
two mechanisms destroy ccdB gene products, simple in- 
troduction of additional amino acids might not. To ad- 
dress this issue we have designed our 237 bp PCR pro- 
duct such that it did 1) neither introduce a frame shift nor; 
2) introduce a premature stop codon but simply inserted 
79 amino acids between proline28 and glycine29 of the 
ccdB gene product. We showed that the addition of these 
79 amino acids was sufficient to destroy the function of 
the ccdB gene product and that additional removal of the 
gene product 3’ of the SmaI restriction site was not man- 
datory. 
In conclusion, we describe a simple and cheap way to 
engineer and propagate an efficient, versatile “home made” 
cloning vector that allows efficient cloning of blunt end- 
ed small to medium sized PCR-products without require- 
ment of advanced skills, special equipment nor reagents. 
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Supplement 
 
Figure S1. Gel electrophoresis of PstI cut vectors pUC18 
and pDONRTM207. Following restriction enzyme digest 
DNA fragments were separated by agar gel electrophoresis 
and visualized using ethidium bromide. 1 kb DNA Ladder 
is shown as reference. 
 
 
Figure S2. Incorporation of the ccdB containing fragment 
removed from pDONORTM207 through PstI digest and in- 
corporation into PstI linearized pUC18. Recombination of 
PstI cut pUC18 with the ccdB fragment. Visualized are 
EcoRI/BamHI digested recombinants (upper part) with 
schemes (lower part) showing the two possible orientations 
of ccdB fragment incorporation. 
 
Strain 
Plasmid
XL1Blue One Shot
®
ccdB SurvivalTM
Puc18 
Puc18ccdB 
 
Figure S3. Plasmid transformation of XL1Blue and One Shot® 
ccdB Survival™ chemically competent cells. Cells were trans- 
formed with indicated plasmids and cultivated on ampicil- 
lin containing LB plates. 
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Table S1. Primer sequences used for polymerase chain reaction. 
Gene product GenBank accession Primer 5‘ → 3’ (added restriction site in italic) Amplicon size (bp) 
Fragment of alkaline 
phosphatase NM_001632 
fw: GCTACGCAGCTCATCTCCAAC 
rev: GAGATGGGTCACAGACGGGT 237 
Protease activated 
receptor 3 (PAR3) NM_010170 
fw: GCTAAAGCTTCACTTGCTGCTCATACATGGAGC 
rev: GCTACTCGAGGGTGCCATGCACAAGTCAGCCAAGC 1302 
Protease activated 
receptor 4 (PAR4) NM_007975 
fw: GCTAAAGCTTGATCCTGGCAGCATGTGCTGGCCG 
rev: GCTACTCGAGTCCTGAGGGTTCAAGAGGGATGTAG 1301 
Thrombomodulin NM_009378 fw: GCTAAAGCTTGTGATAGAGGCTAGCTGCTGT rev: GCTACTCGAGGGATCTCCGCTGTATTTGCC 2221 
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